Identification
NameWF10
Accession NumberDB05389
TypeSmall Molecule
GroupsApproved, Investigational
Description

WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 319.821
Monoisotopic: 317.835121734
Chemical FormulaCl4H2O11
InChI KeyVOWOEBADKMXUBU-UHFFFAOYSA-J
InChI
InChI=1S/4ClHO2.O2.H2O/c4*2-1-3;1-2;/h4*(H,2,3);;1H2/p-4
IUPAC Name
oxidanone hydrate tetrachlorite
SMILES
O.O=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O
Pharmacology
Indication

Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, cancer/tumors (unspecified), HIV infection, and inflammatory disorders (unspecified).

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

WF 10 is a 1: 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory reactions are downregulated.

TargetKindPharmacological actionActionsOrganismUniProt ID
Macrophage erythroblast attacherProteinunknownNot AvailableHumanQ7L5Y9 details
Scavenger receptor cysteine-rich type 1 protein M130ProteinunknownNot AvailableHumanQ86VB7 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Veerasarn V, Khorprasert C, Lorvidhaya V, Sangruchi S, Tantivatana T, Narkwong L, Kongthanarat Y, Chitapanarux I, Tesavibul C, Panichevaluk A, Puribhat S, Sangkittipaiboon S, Sookpreedee L, Lertsanguansinchai P, Phromratanapongse P, Rungpoka P, Trithratipvikul S, Lojanapiwat B, Ruangdilokrat S, Ngampanprasert P: Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial. Radiother Oncol. 2004 Nov;73(2):179-85. [PubMed:15542165 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP0.18ChemAxon
pKa (Strongest Acidic)-4.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity9.02 m3·mol-1ChemAxon
Polarizability3.91 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5575
Blood Brain Barrier+0.9535
Caco-2 permeable-0.5923
P-glycoprotein substrateNon-substrate0.8887
P-glycoprotein inhibitor INon-inhibitor0.985
P-glycoprotein inhibitor IINon-inhibitor0.9956
Renal organic cation transporterNon-inhibitor0.9579
CYP450 2C9 substrateNon-substrate0.7831
CYP450 2D6 substrateNon-substrate0.8516
CYP450 3A4 substrateNon-substrate0.7326
CYP450 1A2 substrateNon-inhibitor0.7958
CYP450 2C9 inhibitorNon-inhibitor0.8319
CYP450 2D6 inhibitorNon-inhibitor0.8739
CYP450 2C19 inhibitorNon-inhibitor0.8037
CYP450 3A4 inhibitorNon-inhibitor0.9522
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9887
Ames testNon AMES toxic0.7006
CarcinogenicityCarcinogens 0.7081
BiodegradationReady biodegradable0.9707
Rat acute toxicity2.3620 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9062
hERG inhibition (predictor II)Non-inhibitor0.9725
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as non-metal chlorites. These are inorganic non-metallic compounds containing a chlorite as its largest oxoanion.
KingdomChemical entities
Super ClassInorganic compounds
ClassHomogeneous non-metal compounds
Sub ClassNon-metal oxoanionic compounds
Direct ParentNon-metal chlorites
Alternative ParentsInorganic oxides
SubstituentsNon-metal chlorite / Inorganic oxide
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Actin binding
Specific Function:
Plays a role in erythroblast enucleation and in the development of the mature macrophages. Mediates the attachment of erythroid cell to mature macrophages, in correlation with the presence of MAEA at cell surface of mature macrophages; This MAEA-mediated contact inhibits erythroid cells apoptosis. Participates to erythroblastic island formation, which is the functional unit of definitive erythr...
Gene Name:
MAEA
Uniprot ID:
Q7L5Y9
Molecular Weight:
45286.895 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Scavenger receptor activity
Specific Function:
Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH...
Gene Name:
CD163
Uniprot ID:
Q86VB7
Molecular Weight:
125449.765 Da
Drug created on November 18, 2007 11:24 / Updated on June 11, 2017 21:00